Argenx

AgomAb raises $74M to develop regenerative pathway modulators
AgomAb raises $74M to develop regenerative pathway modulators
Fierce Biotech
AgomAb
regenerative pathway modulators
Argenx
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:
Biopharma Companies Entering 2021 With New Collabs, Partnerships
Biopharma Companies Entering 2021 With New Collabs, Partnerships
BioSpace
M&A
Argenx
Zai Lab
Dewpoint Therapeutics
Pfizer
CureVac
Bayer
Sanofi
Nurix Therapeutics
Flag link:
3 Biotech Stocks That Could Explode Higher in 2021
3 Biotech Stocks That Could Explode Higher in 2021
Motley Fool
biotech
biotech stocks
clinical trials
FDA
Argenx
Axsome Therapeutics
CRISPR Therapeutics
Flag link:
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Belgium biotech argenx nabs Bayer speedy review voucher for a cool $98M
Fierce Biotech
Argenx
Bayer
FDA
priority reviews
efgartigimod
ITP
Flag link:
10 most valuable R&D projects in the pharmaceutical industry pipeline
10 most valuable R&D projects in the pharmaceutical industry pipeline
Beckers Hospital Review
R&D
drug development
Eli Lilly
Novartis
Argenx
Bristol-Myers Squibb
Vir Biotechnolgy
Biogen
GSK
Iovance
Roche
Flag link:
Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing
Biotech Argenx's autoimmune phase 3 hits goals, teeing up FDA filing
Fierce Biotech
Argenx
efgartigimod
myasthenia gravis
Flag link:
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
Upcoming events – Wave takes on Huntington's and Argenx goes subcutaneous
EP Vantage
Wave Life Sciences
WVE-120101
Huntington's disease
Argenx
efgartigimod
autoimmune disease
Flag link:
Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million
Argenx and Halozyme Ink Multiple Target Deal That Could Hit $540 Million
BioSpace
Argenx
Halozyme Therapeutics
drug delivery
drug development
Flag link:
Should You Be Worried About the Return of Big Pharma Deals?
Should You Be Worried About the Return of Big Pharma Deals?
Motley Fool
GSK
Tesaro
M&A
Big Pharma
JNJ
Argenx
Flag link:
ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab
ASH18: Argenx pens $1.6B biobucks Janssen pact for blood cancer hopeful cusatuzumab
Fierce Biotech
Argenx
Cilag
Janssen
cusatuzumab
ASH2018
blood cancers
Flag link:
Argenx To Raise $300 million in U.S. public offering
Argenx To Raise $300 million in U.S. public offering
CP Wire
Argenx
Flag link:
AbbVie doubles down on cancer project with biotech group Argenx
AbbVie doubles down on cancer project with biotech group Argenx
Yahoo/Reuters
Argenx
AbbVie
ARGX-115
cancer immunotherapy
Flag link:
Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug
Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug
CP Wire
Argenx
AbbVie
ARGX-115
cancer
Flag link:
Argenx Receives Milestone Payment from AbbVie for Preclinical Oncology Drug
Argenx
Flag link:
Argenx IPO haul tops out at $115M, 50% above initial goal
Argenx IPO haul tops out at $115M, 50% above initial goal
Fierce Biotech
Argenx
IPOs
Flag link:
AbbVie Strikes Two Cancer Collaborations: Smart Move?
AbbVie Strikes Two Cancer Collaborations: Smart Move?
Bidness, ETC
AbbVie
cancer
Argenx
ARGX-115
CytomX
probodies
Flag link: